Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.

Shih YT, Xu Y, Chien CR, Kim B, Shen Y, Li L, Geynisman DM.

Pharmacoeconomics. 2019 Jul 8. doi: 10.1007/s40273-019-00824-2. [Epub ahead of print]

PMID:
31286464
2.

First-line Immunotherapy in Metastatic Urothelial Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30131-2. doi: 10.1016/j.euf.2019.04.015. [Epub ahead of print]

PMID:
31103603
3.

Update on perioperative systemic therapy for urothelial carcinoma.

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM.

Clin Adv Hematol Oncol. 2019 Mar;17(3):176-183. Review.

PMID:
30969956
4.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

PMID:
30827746
5.

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.

Osterman CK, Babu DS, Geynisman DM, Lewis B, Somer RA, Balar AV, Zibelman MR, Guancial EA, Antinori G, Yu S, Narayan V, Guzzo TJ, Plimack ER, Vaughn DJ, Fung C, Mamtani R.

Oncologist. 2019 May;24(5):688-690. doi: 10.1634/theoncologist.2018-0561. Epub 2019 Feb 6.

PMID:
30728277
6.

Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma.

Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER.

Clin Adv Hematol Oncol. 2018 Oct;16(10):677-686. Review.

PMID:
30543598
7.

Neoadjuvant chemotherapy for penile cancer enabling organ preservation: A case of individualized management for bilateral lymph node metastasis and a bulky primary tumor.

Asghar AM, McIntosh AG, Kutikov A, Chen DY, Geynisman DM.

Urol Case Rep. 2018 Nov 9;23:3-5. doi: 10.1016/j.eucr.2018.11.002. eCollection 2019 Mar. No abstract available.

8.

Mutations in renal cell carcinoma.

D'Avella C, Abbosh P, Pal SK, Geynisman DM.

Urol Oncol. 2018 Nov 23. pii: S1078-1439(18)30436-8. doi: 10.1016/j.urolonc.2018.10.027. [Epub ahead of print] Review.

PMID:
30478013
9.

Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.

Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT.

Pharmacoeconomics. 2019 Mar;37(3):301-331. doi: 10.1007/s40273-018-0746-y. Review.

PMID:
30467701
10.

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.

Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER.

Eur Urol Oncol. 2018 May;1(1):54-60. doi: 10.1016/j.euo.2018.02.007. Epub 2018 Jun 6.

11.

The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website.

Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M.

Kidney Cancer. 2017 Nov 27;1(2):151-159. doi: 10.3233/KCA-170015.

12.

What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?

Joshi SS, Handorf ER, Smaldone MC, Geynisman DM.

Transl Androl Urol. 2018 Aug;7(4):732-735. doi: 10.21037/tau.2018.06.16. No abstract available.

13.

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

Ghatalia P, Zibelman M, Geynisman DM, Plimack E.

Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310. doi: 10.1177/1758835918788310. eCollection 2018. Review.

14.

Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM.

Eur Urol. 2018 Sep;74(3):387-393. doi: 10.1016/j.eururo.2018.05.025. Epub 2018 Jun 5.

PMID:
29880274
15.

Provider and patient burdens of obtaining oral anticancer medications.

Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN.

Am J Manag Care. 2018 Apr 1;24(4):e128-e133.

16.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

PMID:
29641297
17.

Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis.

Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM.

JAMA Oncol. 2018 May 1;4(5):643-649. doi: 10.1001/jamaoncol.2017.5608.

18.

Chemoimmunotherapy in Metastatic Urothelial Carcinoma.

Geynisman DM, Abbosh PH, Plimack ER, Zibelman M.

Eur Urol. 2018 May;73(5):760-762. doi: 10.1016/j.eururo.2017.12.029. Epub 2018 Jan 10. No abstract available.

PMID:
29331216
19.

Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database.

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC.

J Urol. 2018 May;199(5):1238-1244. doi: 10.1016/j.juro.2017.11.121. Epub 2017 Dec 15.

PMID:
29248557
20.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748

Supplemental Content

Loading ...
Support Center